Keros Therapeutics, Inc.
KROS · XNASCIK 1664710fmd_1HPRBJZQA2STSE1RKTHBKW05ZQManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2019 to Sep 30, 2026, 31 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Total revenues | 10 | 0 | 20 | 0 | 0 | 4 | 244 |
| Research and development | 17 | 34 | 55 | 87 | 135 | 174 | 130 |
| Total operating expenses | 21 | 47 | 76 | 115 | 170 | 214 | 176 |
| Operating income | (11) | (47) | (56) | (115) | (170) | (211) | 68 |
| Interest expense | – | 0 | 0 | 0 | 0 | 0 | – |
| Other non-operating income (expense) | (2) | 1 | (0) | 10 | 17 | 24 | 24 |
| Income before taxes | (12) | (46) | (57) | (105) | (153) | (187) | 92 |
| Income tax expense | 0 | (0) | 2 | 0 | 0 | 0 | 5 |
| Net income from continuing operations | (12) | (45) | (59) | (105) | (153) | (187) | 87 |
| Net income | (12) | (45) | (59) | (105) | (153) | (187) | 87 |
| Net income to common shareholders | (14) | (45) | (59) | (105) | (153) | (187) | 87 |